AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):685-93.

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, Dusek A.

Source

UAB HIV Outpatient Clinic, University of Alabama at Birmingham, CCB 245A, 908 20th Street South, Birmingham, AL 35294-2050, USA. mkilby@uab.edu

Erratum in

AIDS Res Hum Retroviruses. 2003 Jan 1;19(1):83..

Abstract

Enfuvirtide (T-20) is a novel antiretroviral agent that blocks HIV-1 cell fusion. A 28-day randomized dose-comparison study was conducted to determine the safety, pharmacokinetics, and antiviral activity of enfuvirtide in 78 HIV-infected adults, most with extensive treatment experience. Patients received enfuvirtide, added to a failing regimen, either by continuous subcutaneous infusion (CSI: 12.5, 25, 50 or 100 mg/day) or by subcutaneous (SC) injection (50 or 100 mg twice daily). Dose-related decreases in viral load were observed, with a maximum mean reduction from baseline of 1.6 log(10) copies/ml (p< 0.001) seen in the 100 mg bid SC group. Most responses diminished by 28 days. Plasma pharmacokinetics and antiviral responses were more consistent for SC injection than for CSI because of technical difficulties experienced with CSI. Injection site reactions were common but generally mild. These results indicate that enfuvirtide is a promising new therapeutic agent for HIV-infected patients, including those with prior antiretroviral treatment.

PMID:: 12167274; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

HIV/AIDS Medicines - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. [Antivir Ther. 2003]
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, et al. Antivir Ther. 2003 Aug; 8(4):279-87.
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. [AIDS. 2003]
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.
Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, et al. AIDS. 2003 Mar 28; 17(5):691-8.
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. [J Infect Dis. 2004]
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.
Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, et al. J Infect Dis. 2004 Mar 15; 189(6):1075-83. Epub 2004 Mar 2.
Review Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. [Clin Ther. 2004]
Review Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
Fung HB, Guo Y. Clin Ther. 2004 Mar; 26(3):352-78.
Review Enfuvirtide. [Expert Opin Investig Drugs. 2002]
Review Enfuvirtide.
Chen RY, Kilby JM, Saag MS. Expert Opin Investig Drugs. 2002 Dec; 11(12):1837-43.

See reviews... See all...

Cited by 26 PubMed Central articles

Nanotechnology and the Treatment of HIV Infection. [Viruses. 2012]
Nanotechnology and the Treatment of HIV Infection.
Parboosing R, Maguire GE, Govender P, Kruger HG. Viruses. 2012 Apr; 4(4):488-520. Epub 2012 Apr 10.
A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system. [Virol J. 2010]
A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system.
Khetawat D, Broder CC. Virol J. 2010 Nov 12; 7:312. Epub 2010 Nov 12.
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic. [Proc Natl Acad Sci U S A. 2010]
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.
Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD. Proc Natl Acad Sci U S A. 2010 Aug 10; 107(32):14093-8. Epub 2010 Jul 21.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfu...
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
AIDS Res Hum Retroviruses. 2002 Jul 1 ;18(10):685-93.

PubMed
Combinatorial diversity of fission yeast SCF ubiquitin ligases by homo- and hete...
Combinatorial diversity of fission yeast SCF ubiquitin ligases by homo- and heterooligomeric assemblies of the F-box proteins Pop1p and Pop2p.
BMC Biochem. 2002 Aug 7 ;3:22. Epub 2002 Aug 7 .

PubMed
Expression of p21/WAF-1, status of apoptosis and p53 mutation in esophageal squa...
Expression of p21/WAF-1, status of apoptosis and p53 mutation in esophageal squamous cell carcinoma with HPV infection.
Pathol Int. 2002 Jul ;52(7):442-50.

PubMed
Determination of antioxidant potential of volatile extracts isolated from variou...
Determination of antioxidant potential of volatile extracts isolated from various herbs and spices.
J Agric Food Chem. 2002 Aug 14 ;50(17):4947-52.

PubMed
Electrical impedance spectroscopy of the breast: clinical imaging results in 26 ...
Electrical impedance spectroscopy of the breast: clinical imaging results in 26 subjects.
IEEE Trans Med Imaging. 2002 Jun ;21(6):638-45.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

Source

Erratum in

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 26 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information